Expert Details
Auditory Pharmacology & Physiology, Ototoxicity, Tinnitus Therapeutics, Medical Statistics
ID: 729034
United Kingdom
He has had extensive collaboration with the pharmaceutical industry in the development of these models, with the aim of developing and testing therapueics for hearing loss and tinnitus and has contributed to two patent applciations in this area. More recently he has been
involved in determiming the potential sites of actions for specific putatie tinnitolytics - the Volatge Gated Sodium Channels.
Clinically, he has worked on the determiming the effects of aminoglycoside therapy on hearing in patients with cystic fibrosis (CF). He has described the prevalence of loss in this patient group. In addition, he has also worked on the incidence of drug induced hearing loss in neutropenic patients recovering form blood malignancies and in patients recovering from bacterial meningitis. This work has led to a better understanding of the possible sites of action involved in mediating effect ototoxic effects - a necessary first step in the development of possible therapuetics to offset drug and noise auditory deficit in humans. He is also involved in tinnitus trials both for drug and non-drug therapeutics which are ongoing.
Expert worked on collaborative ventures with Glaxo Wellcome and then GlaxoSmithKline in devloping animal models of tinntius and ototoxicity. This led to the patenting of Voltage Gtaed Sodium Channel Blockers for protectanst against noise damage.
World International Patent Application WO02/28394. ‘Voltage dependent sodium channel antagonists as protectants against noise damage. World Intellectual Property Agency. Expert. Expert has consulted with other major pharmaceutical companies in the UK Europe and US, on the suitability of the auditory system as a target for therapeutics. This has included Eli Lilly and other companies whose consultation with is still under confidentiality agreement. Expert has consulted on the development of non-drug therapeutics which has led to an ongoing commercial relationship with this company.
Education
| Year | Degree | Subject | Institution |
|---|---|---|---|
| Year: 1992 | Degree: M.Sc. | Subject: Control Engineering | Institution: University of Bradford |
| Year: 1990 | Degree: PhD | Subject: Auditory Physiology | Institution: University of Keele |
| Year: 1981 | Degree: BSc | Subject: Biology | Institution: University of Manchester |
Work History
| Years | Employer | Title | Department |
|---|---|---|---|
| Years: 2006 to Present | Employer: Undisclosed | Title: Lecturer | Department: Medical School |
Responsibilities:Expert delivers a range of courses within the school, including Clinical Pharmacology and Therapeutics. He also oversees professionalisjm in Phase I of medical students training |
|||
| Years | Employer | Title | Department |
| Years: 2002 to 2006 | Employer: University of Leicester | Title: Independent Research Scientist | Department: Cell Physiology and Pharmacology |
Responsibilities:Running projects in clinical and experimental auditory studies in hearing loss and tinnitus |
|||
| Years | Employer | Title | Department |
| Years: 1993 to 2002 | Employer: MRC Toxicology Unit | Title: Research Scientist Band 3 | Department: Neurotoxicology |
Responsibilities:Running projects in clinical and experimental auditory studies in hearing loss and heraing protection |
|||
| Years | Employer | Title | Department |
| Years: 1991 to 1993 | Employer: University of Bradford | Title: Honorary Research Scientist | Department: Control Engineering |
Responsibilities:Developing techniques for non-invasive prediction of ovulation |
|||
| Years | Employer | Title | Department |
| Years: 1987 to 1989 | Employer: University of Aston | Title: Research Scientist | Department: Pharmacy |
Responsibilities:Experimental models of ototoxicity |
|||
Government Experience
| Years | Agency | Role | Description |
|---|---|---|---|
| Years: 1993 to 1998 | Agency: MRC Toxicology Unit | Role: Research Scientist | Description: Expert was employed by the MRC to build on the bridge between experimental and clinical neurotoxicologicla studies |
International Experience
| Years | Country / Region | Summary |
|---|---|---|
| Years: 2007 to Present | Country / Region: Germany | Summary: Contributor to TRI workshops on development of pharmaceutical treatments for tinnitus |
Career Accomplishments
| Associations / Societies |
|---|
| He is a member of the BSA in the UK |
| Publications and Patents Summary |
|---|
| He has over 30 publications in this field and two patent applications, with four papers in preparation. |
Additional Experience
| Training / Seminars |
|---|
| Setting up a number of meetings on Ototoxicity directed at the pharamceutical industry and clinicians. |
| Marketing Experience |
|---|
| Pharmaceutical Industry - Collaborative projects and consultation on both experimental and clinical projects with a focus on the auditory system (eight major companies). |
| Other Relevant Experience |
|---|
| Contributor to DHSS (UK) 2005 report on future of audiological medicine Knowledge of Medical statistics informing study design and data analysis. Currently studying towards Msc in this field. |